Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk by Weiderpass, E et al.
Serum levels of insulin-like growth factor-I, IGF-binding protein 1
and 3, and insulin and endometrial cancer risk
E Weiderpass*,1,2, K Brismar
3, R Bellocco
2, H Vainio
1 and R Kaaks
1
1International Agency for Research on Cancer, 150 Cours Albert Thomas, F-69372 Lyon Ce ´dex 08, France;
2Department of Medical Epidemiology,
Karolinska Institutet, Nobelva ¨g 12A, Box 281, Stockholm S-171 77, Sweden;
3Department of Molecular Medicine, Endocrine and Diabetes Unit,
Karolinska Hospital, Stockholm S-17176, Sweden
Insulin-like growth factor-I (IGF-I) and IGF-binding protein-1 and 3 (IGFPB-1, IGFPB-3) are expressed in normal and neoplastic
endometrium. Their role and the role of insulin in the aetiology of endometrial cancer, is unclear. We performed a population-based
case-control study in Sweden, including 288 endometrial cancer patients and 392 control women and analysed total serum IGF-I,
IGFBP-1, IGFBP-3, insulin and BMI levels stratified by disease and hormone replacement therapy status (HRT). Non-parametric
statistical tests and logistic regression analyses were performed to assess associations with endometrial cancer. There were no
substantial differences between the mean serum levels of IGF-I between cases (115.5, s.d. 61.3) and controls (110.6; s.d. 50.4;
Wilcoxon P¼0.84), or between subgroups of women classified according to other risk factors for endometrial cancer. There were
no trends of increasing risk according to quartiles of IGF-I, IGFBP-1, IGFBP-3 and insulin serum levels. There was an increasing risk of
endometrial cancer according to the serum levels of IGFBP-1, which was observed only among women who had ever used HRT.
Serum IGF-I, IGFBP-1, IGFBP-3 and insulin levels seem unrelated to endometrial cancer risk. Among users of HRT, increasing IGFBP-1
levels seem to increase endometrial cancer risk.
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Endometrial cancer has high incidence rates in Western,
industrially developed societies. In these countries, obesity has
been associated with a 2-to-5-fold increase in endometrial cancer
risk in both pre- and postmenopausal women (IARC, 2002) and
has been estimated to account for about 40% of endometrial
cancer incidence (Bergstorm et al, 2001). Apart from excess
weight, epidemiological evidence suggests that lack of regular
physical activity may also be a risk factor (IARC, 2002).
A major metabolic link between obesity, lack of physical activity,
and development of ovarian androgen excess is chronic hyper-
insulinaemia. Obesity and physical inactivity lead to insulin
resistance, and increased fasting and nonfasting insulin levels.
Furthermore, type II diabetes mellitus (Type II DM) – a condition
associated with chronic endogenous insulin excess for many years
both before and after diagnosis – is a well-established risk factor
for endometrial cancer (Persson and Adami, 2002). One previous
case–control study showed that risk of endometrial cancer was
increased among women (also nondiabetic) who had elevated
fasting serum levels of C-peptide, a marker of pancreatic
(pro)insulin secretion (Troisi et al, 1997).
In addition to insulin, there is evidence that endometrial cancer
development is related to alterations in insulin-like growth factor-I
(IGF)-I metabolism. Oestrogens increase endometrial cell prolif-
eration by inducing the production of IGF-I in stromal tissue, and
it is IGF-I that, in turn, provides the major mitogenic stimulus.
Progesterone opposes these effects by inducing the local synthesis
of IGFBP-1 (Giudice, 1994; Lee et al, 1997) – the most abundant
IGF-binding protein in endometrial tissue. Insulin inhibits IGFBP-
1 synthesis in liver and other tissue, and this may be one key
mechanism through which insulin increases endometrial cancer
risk (Brismar et al, 1994; Lee et al, 1997).
We present here results of a population-based case–control
study in Sweden, in which we assessed the relationships of
endometrial cancer risk with serum levels of fasting insulin, IGF-I,
and IGFBP-1, as well as IGFBP-3, IGF’s major binding protein in
the circulation. We also explored whether these associations differ
in subgroups of women who used exogenous hormones (oral
contraceptives (OCs) and hormone replacement therapy (HRT)).
SUBJECTS AND METHODS
Study population
Our study included women aged 50–74 years, resident between
February 1996 and November 1997 in 12 Swedish counties on the
coasts of the Gulf of Bothnia, the Baltic Sea, and the largest
Swedish lakes. Women were eligible if they were born in Sweden,
had no prior hysterectomy, and had no previous history of cancer.
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et al, 2000). We assumed that the intake of organochlorine
compounds through ingestion of possibly contaminated fish would
be higher in these fish-producing counties than in other parts of
Sweden.
Women with incident histopathologically confirmed endome-
trial cancer diagnosed between February 1996 and November 1997
were identified through a network of personnel at the 26
departments of gynaecology/gynaecology–oncology in the study
area (one of the departments did not collaborate). The health-care
system in Sweden is organised in such a way that people must seek
services in the health-care unit/hospital closest to their home.
Therefore, it is highly unlikely that cancer cases residing in the
study area would be operated outside the study area. A total of 396
cases were reported, approximately 95% of the number expected
on the basis of national incidence rates (National Board of Health
and Welfare, 1998). Of these, 288 (73%) were contacted before
surgery, volunteered to donate blood samples, and subsequently
completed the study questionnaire a few months after surgery; 41
patients refused to participate and 67 cases were not approached
(due to failure of the medical staff to collect a blood sample before
surgery).
Population controls, who were resident in the study area,
were randomly selected from a continuously updated population
register and frequency matched to cases by 5-year age groups.
Controls were not matched to cases by geographic area
of residence (county) or any other characteristic. The period of
control recruitment coincided with that of the cases, since
we sampled and enrolled controls in four phases: the spring
of 1996, the fall of 1996, the spring 1997, and the fall 1997. In
contrast to the cases, the controls were approached first
for questionnaire information, and subsequently asked to donate
a fasting blood sample. Of 688 control women selected, 505
(73.4%) responded to the questionnaire, and 438 (63.7%) also
agreed to donate blood samples. After exclusion of 46 women
because of prior hysterectomy, 392 control women were included
in the study.
The self-administered study questionnaire requested informa-
tion on weight 1 year preceding the interview, height, reproductive
history, smoking, physical activity 1 year preceding the interview,
medical history (as having had a diagnosis of diabetes mellitus),
and use of exogenous hormone (of HRT and OCs), among others.
Information about use of HRT and OCs included brand, dosage,
date of first and last use of each treatment period, and – for HRT –
treatment indication. Recall was aided by picture charts of all
brands of HRT and OCs commercially available in Sweden during
the years 1960–1995. Use of the same methodology (i.e.
questionnaire and picture charts to access history of HRT and
OCs use) was tested in previous studies, where it identified
differential patterns of endometrial cancer risk and different
histopathological features of endometrial tumours according to the
type of hormones used and the route of administration
(Weiderpass et al, 1999a–c).
Missing information was supplemented by a telephone interview
in approximately 50% of cases and controls.
The Ethical Committee, Uppsala University and the Ethical
Committee, Karolinska Institutet, Stockholm, Sweden approved
the study design. Only patients who gave informed consent were
included in the study.
Blood sampling
Blood samples from fasting case women were drawn at the hospital
departments before surgery or any cancer treatment and
from controls at a primary health-care unit or at home. Case
patients and control women were requested to fast overnight, for
at least 8h.
Laboratory analysis
Laboratory analysts in charge of measuring IGF-I and IGFBP-1,
IGFBP-3, and insulin were blinded to the case–control status of
the samples, as well as other subject characteristics.
Total IGF-I Serum concentrations of IGF-I were determined by
RIA after separation of IGFs from IGFBPs by acid ethanol
extraction and cryoprecipitation (Bang et al, 1991). To minimise
the interference of remaining IGFBPs in the acid ethanol extracts,
Des(1–3)IGF-I was used as a radioligand. The recovery of
unlabelled IGF-I was 95% and the intra- and interassay coefficients
of variation were 5 and 11%, respectively. The lowest detectable
quantity of IGF-I was 0.01ngtube
 1. Crossreactivity with insulin
was less than 0.1% and with IGF-II less than 2%.
Serum levels of IGF-I are age dependent, decreasing with age.
Thus, IGF-I values were also expressed as standard deviation (s.d.)
scores, calculated from the regression of the values of 247 healthy
adult subjects (Hilding et al, 1995).
IGFBP-1 Serum IGFBP-1 concentrations were determined by RIA
as described by Povoa et al (1986). The intra- and interassay
coefficients of variation were 3 and 11%, respectively, and the
detection limit was 3.0mgl
 1. Crossreactivity with IGFBP-2 and
IGFBP-3 was less than 0.5 and 0.05%, respectively. The geometrical
mean and range of IGFBP-1 were 34 and 12–91mgl
 1 in healthy
subjects, aged 20–66 years (Hall et al, 1988).
IGFBP-3 IGFBP-3 was analysed using a commercial RIA (DSL
6700, Diagnostic System Laboratories, Webster, TX, USA). The
mean and normal range was 3.8 and 2.3–5.3mgl
 1 in women.
Insulin Serum insulin was measured using an RIA technique
(RIA 100, Pharmacia, Uppsala, Sweden). The detection limit was
o2mUml
 1. The within-assay CV was 5.8 for a mean value of
11.6mUml
 1 and 5.7 for a mean value of 65.2mUml
 1.
Statistical analysis
As the distributions of IGF-I, IGFBP-1, IGFBP-3, and insulin
measurements were heavily skewed, we used the nonparametric
two-sample Wilcoxon’s test for unpaired data to conduct
unadjusted comparisons of IGF-I, IGFBP-1, IGFBP-3, insulin levels
in case and control women and in ever, never, and former users of
HRT. Quartiles of the distribution of the IGF-I, IGFBP-1, IGFBP-3,
and insulin levels were calculated based on the values assumed
from the controls (reference group), and included in the logistic
regression analysis as dummy variables.
We first estimated age-adjusted odds ratios (ORs) of IGF-I,
IGFBP-1, IGFBP-3, and insulin serum levels, and subsequently
included in the logistic regression models variables known or
hypothetically associated with endometrial cancer risk, and that
may be in the ‘IGF-I, IGFBP-1, IGFBP-3, insulin, and endometrial
cancer pathway. These variables were age (as a continuous
variable), age at menarche (as a continuous variable), menopausal
status (pre- or postmenopausal), body mass index (BMI, that is,
weight in kgheight
 1 in m
2, as a continuous variable), physical
activity levels, use of oral contraceptives (ever or never), clinical
history of diabetes mellitus and hypertension (self-reported), and
use of different HRT (classified according to ever or never
exposure to the following compounds: oestrogens without
progestins, oestrogens with cyclic addition of progestins, oestro-
gens with continuous addition of progestins, progestins without
oestrogens, oral oestriol, and vaginal use of oestriol, dienoestrol, or
oestradiol. Ever users were further classified as ‘current users’,
meaning control women who were using HRT at the time of blood
sample collection and case women who were using HRT at the time
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cancer diagnosis).
We analysed the effect of all the variables mentioned above on
IGF-1, IGFBPs, and insulin among control women only, to
understand which were strong determinants of these endogenous
hormone levels among women without cancer. In these analyses,
the use of HRT and OCs was the only women’s characteristic
strongly influencing all endogenous hormones levels of interest
(IGF-1, IGFBPs, and insulin). Therefore, here we will also present
stratified analysis according to the use of HRT and OCs.
Maximum-likelihood estimates of ORs and 95% confidence
intervals were produced using the unconditional logistic regres-
sion model procedure in Stata 7 (Breslow and Day, 1980; Stata,
2000).
RESULTS
Compared to controls, cases were slightly older, had a higher age at
menopause, a lower parity, and a greater BMI. Proportionally,
more cases than controls reported being nulliparous, having never
smoked or used oral contraceptives, having used HRT, having a
history of diabetes mellitus or hypertension, and being extremely
sedentary (Table 1).
The correlation coefficients between the different endogenous
hormones studied did not differ substantially from those
calculated separately for cancer patients and controls (Table 2).
Table 3 presents the number of patients having samples
analysed for IGF-I, IGFBP-1, IGFBP-3, and insulin, showing means
(and s.d.), medians, and range of results among endometrial
cancer cases and control women. Overall, IGFBP-1 levels were
higher among the cancer cases than among control women. For the
other endogenous hormone levels studied, the differences between
cases and controls were not statistically significant.
We further analysed separately the levels of endogenous
hormones according to use of HRT (ever, never, and former use)
and oral contraceptives (ever and never) (Table 4). Regardless of
control status, women who used HRT either at the time of the
blood donation or previously presented significantly higher IGF-I
levels than women who never used HRT, and a similar difference
was observed between women who did or who did not use OCs.
The exclusion of women who were using HRT at the time of blood
donation from the analysis did not alter these differences
substantially. Likewise, but among the control women only, those
never users of HRT or OCs had lower levels of IGFBP-3 and higher
levels of IGFBP-1 than HRT users. Moreover, only the HRT users
had lower levels of insulin.
The higher levels of IGFBP-1 among endometrial cancer cases
were restricted to those women who had used HRT and/or OC.
Among HRT or OC users, cases also had lower IGFBP-3 levels than
controls, although the difference did not reach statistical
significance. Among never users of HRT, insulin levels were
higher among cases compared to controls, whereas among HRT
users the opposite was observed: cases had lower insulin levels
than controls. In all subgroups of HRT and/or OC use, cases had
higher BMI than controls, although cases who had used HRT had
slightly lower BMI than cases who never used HRT (Table 4).
Overall, all subgroups of HRT and OC users combined, there
was no significant trend of increasing or decreasing the risk of
endometrial cancer over quartiles of the distribution of IGF-I,
IGFBP-1, IGFBP-3, and insulin serum (Table 5). Furthermore,
results from the analysis including mutual adjustment IGFBP-1
and insulin serum levels (i.e. results for IGFBP-1 adjusted for
insulin levels and results from insulin levels adjusted for IGFBP-1
Table 1 Selected characteristics of endometrial cancer patients and
control women
Cases Controls
Cases/controls
a Mean (s.d.)
Age (years) 288/392 64.7 (7.2) 63.0 (7.0)
Age at menopause
b 258/363 51.2 (3.3) 50.3 (3.7)
Parity (all women) 288/381 1.9 (1.2) 2.2 (1.2)
Age at last birth
c 288/381 30.0 (5.5) 30.0 (5.5)
Body mass index
d 288/291 27.6 (5.0) 25.9 (4.4)
Cases Controls
Proportions
Premenopausal 288/392 7.7% 6.4%
Nulliparous 288/381 14.6% 9.4%
Ever smoked 288/392 29.2% 39.5%
Ever used OCs 288/392 71 (24.7%) 154 (39.3%)
Ever used HRT
e 288/392 150 (52.1%) 166 (42.3%)
Diabetes mellitus
f 288/392 10.4% 3.1%
Hypertension
f 281/391 35% 24%
Extreme sedentarism
g 208/366 20 (9.6%) 4 (1.1%)
aNumber of study subjects for whom data are available for each variable.
bExcluding
22 cases and 25 controls who were premenopausal.
cAmong parous.
dWeight in
kgheight
 1 in m
2.
eHRT¼hormone replacement therapy. Women may have used
more than one kind of oestrogen replacement.
fSelf-reported.
gAt 1 year before
study enrolment in a scale of physical activity ranging from 0 to 4.
Table 2 Pearson’s correlation coefficients between the various hormone
levels in the entire study population (endometrial cancer cases and control
women)
a
INSULIN
(ngml
 1)
IGFBP-1
(ngml
 1)
IGF-I
(ngml
 1)
IGFBP-1 (ngml
 1)  0.22 1.0
IGF-I (ngml
 1) 0.04  0.09 1.0
IGFBP-3 (ngml
 1) 0.09  0.18 0.35
aThe correlation coefficients calculated separately for endometrial cancer cases and
control women were not substantially different from the coefficients presented
above (cases and controls together).
Table 3 Distribution of IGF-I, IGFBP-1, IGFBP-3, and insulin among endometrial cancer cases and control women
Cases (n¼288) Controls (n¼392)
n Mean (s.d.) Median Range n Mean (s.d.) Median Range P-value*
IGF-I (ngml
 1) 274 115.5 (61.3) 103.0 22–403 313 110.6 (50.4) 101.0 18–373 0.8422
IGFBP-1 (ngml
 1) 274 32.2 (20.4) 28.2 1.9–101 313 28.9 (19.1) 24.6 2.7–112 0.0430
IGFBP-3 (ngml
 1) 257 6.1 (2.3) 5.7 0.1–12.4 286 6.1 (2.3) 6.0 0.9–12.4 0.6192
Insulin (ngml
 1) 260 14.0 (13.9) 10.0 2.0–119.0 296 15.3 (16.7) 10.0 2.0–149.0 0.6351
*P-value for the difference between cases and controls (within lines).
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OCs
Cases (n¼288) Controls (n¼392)
n Mean (s.d.) Median P-value* Range n Mean (s.d.) Median P-value* Range P-value**
IGF-I (ngml
 1)
HRT never used 129 107.9 (55.7) 98.0 0.0584 27–333 203 100.8 (45.5) 94.0 0.000 18–290 0.5052
HRT ever used 145 122.2 (65.3) 108.0 22–403 110 128.8 (54.2) 118.5 57–373 0.1212
HRT former user 116 122.8 (62.5) 111.0 0.0382 22–381 25 129.2 (56.2) 109.0 0.0168 57–278 0.5708
OC never used 204 112.8 (61.3) 99.0 0.1150 27–403 203 105.8 (53.6) 94.0 0.0007 18–373 0.3703
OC ever used 70 123.4 (61.0) 110.0 22–333 110 119.4 (42.7) 113.5 41–290 0.8973
IGFBP-1 (ngml
 1)
HRT never used 129 33.1 (21.6) 26.9 0.6611 1.9–98.6 203 32.3 (19.4) 30.9 0.000 4.0–112.0 0.9425
HRT ever used 145 31.3 (19.4) 27.2 3.2–101.0 110 22.4 (16.6) 17.1 2.7–82.9 0.0000
HRT former user 116 31.4 (20.2) 27.5 0.6062 3.9–101 25 22.7 (18.0) 13.6 0.0078 2.7–62.2 0.0312
OC never used 204 32.2 (20.2) 28.2 0.9484 3.9–101 203 32.4 (20.1) 30.7 0.0000 2.7–112.0 0.8821
OC ever used 70 32.2 (21.2) 29.0 1.9–95.4 110 22.6 (15.1) 20.6 4.0–79.7 0.0019
IGFBP-3 (ngml
 1)
HRT never used 120 6.1 (2.3) 5.7 0.8092 0.1–11.9 177 5.8 (2.2) 5.4 0.0003 1.6–11.5 0.3469
HRT ever used 137 6.1 (2.3) 5.7 2.2–12.4 109 6.8 (2.4) 6.4 0.9–12.4 0.0179
HRT former user 112 6.1 (2.3) 5.7 0.9415 2.2–12.4 25 6.8 (2.4) 7.3 0.0154 0.9–11.2 0.0950
OC never used 192 6.1 (2.2) 5.7 0.6191 1.8–12.4 187 6.0 (2.4) 5.6 0.0500 0.9–12.4 0.6036
OC ever used 65 6.0 (2.4) 5.6 0.1–11.4 99 6.4 (2.2) 6.4 1.6–12.0 0.1399
Insulin (ngml
 1)
HRT never used 120 14.8 (13.4) 10.0 0.0727 7.0–81.0 187 11.0 (9.2) 9.0 0.0000 2.0–64.0 0.0024
HRT ever used 140 13.2 (14.2) 9.0 2.0–119.0 109 22.6 (22.9) 16.0 3.0–149.0 0.0000
HRT former user 115 12.3 (11.7) 9.9 0.0773 2.0–71.0 25 22.3 (22.6) 16.0 0.0007 5.0–90.0 0.0081
OC never used 194 14.2 (14.1) 10.0 0.5930 2.0–119.0 194 15.6 (18.7) 10.0 0.5392 2.0–149.0 0.9573
OC ever used 66 13.3 (12.9) 10.0 2.0–81.0 102 14.6 (11.9) 10.0 3.0–71.0 0.3581
HRT¼hormone replacement therapy; OC-oral contraceptives. *P-value for the difference within categories in each column (i.e. comparing cases who used HRT with cases who
never used HRT or who were former users of HRT, or ever vs never users of OCs within cases and within controls). **P-value for the difference between cases and controls
(within lines).
Table 5 Serum levels of IGF-I, IGFBP-1, IGFBP-3, insulin, and risk of endometrial cancer
Quartiles of the distribution among control women*
234
Age-adjusted and multivariate models** 1 (reference) OR (95 CI%)* OR (95 CI%)* OR (95 CI%)* P trend
IGF-I
Model A 1.0 0.63 (0.39–1.01) 0.84 (0.53–1.33) 0.98 (0.62–1.53) 0.85
Model B 1.0 0.51 (0.29–0.89) 0.66 (0.38–1.17) 0.89 (0.52–1.53) 0.86
Model C 1.0 0.59 (0.32–1.10) 0.82 (0.44–1.54) 0.86 (0.46–1.58) 0.78
IGFBP-1
Model A 1.0 0.96 (0.59–1.56) 1.29 (0.81–2.07) 1.43 (0.90–2.27) 0.07
Model B 1.0 1.16 (0.64–2.11) 1.50 (0.85–2.63) 1.63 (0.90–2.94) 0.07
Model C 1.0 0.91 (0.45–1.81) 1.21 (0.63–2.35) 1.09 (0.54–2.20) 0.85
IGFBP-3
Model A 1.0 0.93 (0.58–1.50) 0.76 (0.47–1.24) 0.90 (0.55–1.46) 0.51
Model B 1.0 0.99 (0.56–1.74) 0.81 (0.45–1.48) 1.08 (0.60–1.92) 0.95
Model C 1.0 0.77 (0.41–1.46) 0.80 (0.41–1.56) 1.22 (0.63–2.36) 0.51
Insulin
Model A 1.0 1.18 (0.72–1.95) 1.09 (0.65–1.83) 1.04 (0.62–1.75) 0.94
Model B 1.0 1.13 (0.62–2.08) 0.77 (0.40–1.51) 0.64 (0.32–1.24) 0.07
Model C 1.0 1.24 (0.62–2.50) 0.87 (0.40–1.90) 0.72 (0.33–1.58) 0.19
OR¼odds ratio. *The first quartile is always considered as a reference category (1.0). The quartiles are: IGF-I (ngml
 1): o77.5, 77.5–100, 101–134, and 4134. IGFBP-1
(ngml
 1): o14.2, 14.2–24.5, 24.6–38.6, and 438.6. IGFBP-3 (ngml
 1): o4.5, 4.5–5.9, 6–7.6, and 47.6. Insulin (mgml
 1): o6, 6–9.9, 10–16.9, and 416.9. ** The
multivariate models include indicators for: Model (A) age, Model (B) age, BMI, diabetes mellitus, and physical activity, Model (C) as in Model (B), adding menopausal status,
different types of hormone replacement therapy and oral contraceptives.
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mutual adjustment (data not shown).
Although globally there were no clear associations of endome-
trial cancer risk with levels of the various peptides, certain
differences are shown in Table 6 by HRT status. Among HRT
users, higher IGF-I and IGFBP-3 levels were associated with a
(nonsignificant) decreased risk of endometrial cancer, while
among never users there was no such association. Furthermore,
among HRT users increasing levels of IGFBP-1 and lower levels of
insulin were associated with increased endometrial cancer risk,
while among nonusers the risk was not associated with IGFBP-1
and directly associated with insulin. The differences between HRT
users and nonusers in the relationships of risk with IGFBP-1 and
insulin were statistically significant (P for interaction¼0.02 for
IGFBP-1 and Po0.000 for insulin).
We found no clear evidence of an interaction between the use of
oral contraceptives levels of IGF-I, IGFBPs, and insulin (Table 7).
Women in the two highest quartiles of the IGFBP-1 distribution
Table 6 Serum levels of IGF-I, IGFBP-1, IGFBP-3, insulin, and risk of endometrial cancer, according to use of HRT (ever or never used during lifetime)
Quartiles (among controls)
12 3 4
Age-adjusted and multivariate models** OR (95 CI%) OR (95 CI%) OR (95 CI%) OR (95 CI%) P trend
IGF-I (P interaction IGF1/HRT¼0.22)
HRT ever users
Cases/controls 39/13 28/30 29/27 49/40
Model A 1.0 0.32 (0.014–0.72) 0.39 (0.17–0.89) 0.45 (0.21–0.97) 0.18
Model B 1.0 0.24 (0.09–0.64) 0.36 (0.13–0.96) 0.38 (0.16–0.92) 0.17
Model C 1.0 0.46 (0.14–1.48) 0.62 (0.19–2.03) 0.43 (0.15–1.23) 0.19
HRT never users
Cases/controls 45/65 23/48 34/50 27/40
Age (years) 1.0 0.73 (0.39–1.36) 1.08 (0.60–1.95) 1.08 (0.57–2.03) 0.65
Age, BMI, DM, PA 1.0 0.54 (0.24–1.18) 0.78 (0.36–1.67) 1.22 (0.55–2.69) 0.66
Age, BMI, DM, PA, MP, OC 1.0 0.59 (0.26–1.32) 0.98 (0.44–2.20) 1.44 (0.62–3.31) 0.38
IGFBP-1 (P interaction BP1/HRT¼0.02)
HRT ever users
Cases/controls 31/43 30/31 40/19 44/17
Model A 1.0 1.30 (0.66–2.58) 2.69 (1.29–5.60) 3.29 (1.56–6.93) o0.0001
Model B 1.0 1.50 (0.64–3.51) 3.76 (1.52–9.30) 4.12 (1.60–10.61) 0.001
Model C 1.0 1.58 (0.56–4.44) 6.24 (1.80–21.66) 3.84 (1.10–13.42) 0.012
HRT never users
Cases/controls 26/37 23/45 37/59 43/62
Model A 1.0 0.72 (0.35–1.47) 0.86 (0.44–1.64) 0.94 (0.49–1.78) 0.94
Model B 1.0 0.85 (0.35–2.03) 0.82 (0.37–1.81) 0.94 (0.40–2.19) 0.89
Model D 1.0 0.65 (0.25–1.72) 0.53 (0.22–1.27) 0.54 (0.21–1.38) 0.19
IGFBP-3 (P interaction BP3/HRT¼0.09)
HRT ever users
Cases/controls 33/15 41/27 28/29 35/38
Model A 1.0 0.66 (0.30–1.45) 0.43 (0.19–0.96) 0.43 (0.20–0.92) 0.02
Model B 1.0 0.85 (0.33–2.20) 0.49 (0.18–1.30) 0.55 (0.22–1.38) 0.12
Model C 1.0 0.97 (0.29–3.24) 0.56 (0.17–1.88) 0.91 (0.29–2.94) 0.73
HRT never users
Cases/controls 33/51 31/49 28/45 28/32
Model A 1.0 0.97 (0.52–1.83) 0.97 (0.51–1.86) 1.33 (0.68–2.61) 0.46
Model B 1.0 0.86 (0.40–1.88) 0.78 (0.34–1.78) 1.54 (0.68–3.52) 0.42
Model D 1.0 0.68 (0.30–1.56) 0.86 (0.36–2.07) 1.53 (0.64–3.64) 0.32
Insulin (P interaction ins/HRT¼0.000)
HRT ever users
Cases/controls 29/13 44/25 38/20 29/51
Model A 1.0 0.75 (0.33–1.71) 0.82 (0.35–1.93) 0.24 (0.11–0.54) o0.0001
Model B 1.0 0.72 (0.26–1.97) 0.55 (0.18–1.66) 0.13 (0.04–0.40) o0.0001
Model C 1.0 0.72 (0.18–2.83) 0.44 (0.07–1.98) 0.11 (0.03–0.49) o0.0001
HRT never users
Cases/controls 15/43 39/62 29/56 37/26
Model A 1.0 1.79 (0.88–3.65) 1.47 (0.70–3.08) 3.97 (1.82–8.66) 0.002
Model B 1.0 1.52 (0.65–3.56) 0.88 (0.34–2.30) 2.18 (0.81–5.84) 0.29
Model D 1.0 1.60 (0.64–3.98) 1.07 (0.38–3.03) 2.44 (0.85–7.07) 0.18
HRT¼hormone replacement therapy; OC¼oral contraceptives. **The multivariate models include indicators for: Model (A) age. Model (B) age, body mass index (BMI),
diabetes mellitus, and physical activity. Model (C) same as Model (B) adding menopausal status, types of HRT used (unopposed oestrogens, cyclic combined, continuous
combined), and use of OCs. Model (D) same as Model (C) with or without HRT.
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clear association was observed among those who never used OCs
(P for interaction¼0.08). There was no indication of any
differential effect of insulin according to the use of oral contra-
ceptives (P for interaction¼0.82).
DISCUSSION
This first large case–control study on endometrial cancer risk in
relation to serum levels of IGF-I and IGF-binding proteins-1 and -3,
globally showed no association of risk with any of these peptides.
Furthermore, risk globally appeared not to be associated with
serum insulin levels. Other case–control differences in our study
in relation to age, age at menopause, parity, BMI, smoking history
use of OCs and HRT, history of diabetes, hypertension, and
sedentarism are fully in line with known epidemiological associa-
tions (Persson and Adami, 2002).
Considerable evidence suggests that these relationships of risk
with lifestyle may be mediated by alterations in the metabolism of
endogenous sex steroids. Endometrial cancer risk is increased
among both pre- and postmenopausal women who have elevated
plasma androstenedione and testosterone, and among postmeno-
pausal women with increased levels of circulating oestrone and
estradiol (Persson and Adami, 2002).
Given the increased risk of endometrial cancer among type II
diabetics and obese women, and given the results from the
previous case–control study by Troisi et al (1997), we anticipated
that elevated insulin would have been related to higher endome-
trial cancer risk. We have postulated a number of mechanisms
through which this increase might occur (Kaaks et al, 2002).
The anticipated direct association of risk with serum insulin
levels was clearly present only when we restricted our statistical
analyses to women who never used any oestrogen or oestrogen
plus progestogen HRT. In this subgroup, we also observed an
inverse association with levels of IGFBP-1, but only after multiple
Table 7 Serum levels of IGF-I, IGFBP-1, IGFBP-3, insulin, and risk of endometrial cancer, according to use of oral contraceptives (OC, ever ,or never used
during lifetime)
OR (95 CI%)
a
12 3 4P trend
Quartiles and IGF-I (P interaction IGF1/OC¼0.17)
Ever used OC
Cases/controls: 70/110
Age (years) 1.0 0.30 (0.11–0.81) 0.33 (0.13–0.86) 0.58 (0.23–1.49) 0.58
Age, diabetes mellitus, HRT types, BMI 1.0 0.22 (0.07–0.68) 0.28 (0.10–0.82) 0.40 (0.14–1.18) 0.63
Never used OC
Cases/controls: 204/203
Age (years) 1.0 0.78 (0.45–1.35) 1.18 (0.68–2.05) 1.07 (0.63–1.80) 0.58
Age, diabetes mellitus, HRT types, BMI 1.0 0.70 (0.39–1.25) 1.09 (0.61–1.94) 0.86 (0.49–1.52) 0.74
IGFBP-1 (P interaction BP1/OC¼0.08)
Ever used OC
Cases/controls: 70/110
Age (years) 1.0 0.98 (0.41–2.39) 1.79 (0.76–4.20) 3.26 (1.39–7.68) 0.004
Age, diabetes mellitus, HRT types, BMI 1.0 0.97 (0.35–2.74) 1.80 (0.67–4.84) 5.24 (1.90–14.48) 0.99
Never used OC
Cases/controls: 204/203
Age (years) 1.0 0.86 (0.47–1.60) 1.03 (0.58–1.85) 0.98 (0.55–1.73) 0.89
Age, diabetes mellitus, HRT types, BMI 1.0 1.06 (0.55–2.04) 1.38 (0.74–2.56) 1.50 (0.78–2.88) 0.43
IGFBP-3 (P interaction BP3/OC¼0.19)
Ever used OC
Cases/controls: 65/99
Age (years) 1.0 0.54 (0.21–1.39) 0.52 (0.21–1.27) 0.40 (0.15–1.01) 0.06
Age, diabetes mellitus, HRT types, BMI 1.0 0.49 (0.17–1.43) 0.44 (0.16–1.22) 0.20 (0.06–0.62) 0.99
Never used OC
Cases/controls: 192/187
Age (years) 1.0 1.08 (0.62–1.86) 0.88 (0.49–1.59) 1.24 (0.70–2.22) 0.62
Age, diabetes mellitus, HRT types, BMI 1.0 0.93 (0.52–1.66) 0.79 (0.42–1.46) 1.26 (0.69–2.30) 0.53
Insulin (P interaction ins/OC¼0.82)
Ever used OC
Cases/controls: 66/102
Age (years) 1.0 0.94 (0.37–2.37) 1.02 (0.40–2.62) 0.68 (0.26–1.79) 0.47
Age, diabetes mellitus, HRT-types, BMI 1.0 0.87 (0.31–2.49) 0.97 (0.32–2.91) 0.38 (0.12–1.22) 0.16
Never used OC
Cases/controls: 194/194
Age (years) 1.0 1.32 (0.72–2.39) 1.12 (0.60–2.08) 1.27 (0.68–2.36) 0.67
Age, diabetes mellitus, HRT-types, BMI 1.0 1.12 (0.58–2.16) 0.76 (0.37–1.56) 0.76 (0.36–1.57) 0.17
HRT¼hormone replacement therapy.
aOdds ratios and 95% confidence intervals for models including age only, and age, history of diabetes mellitus, use of different HRT types
and body mass index (BMI).
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fully in line with observations from a pooled study of prospective
cohorts in the USA (New York), Northern Sweden (Umea ˚), and
Italy (Milan), where an approximate five-fold increase in risk was
observed for women in the highest quintile of C-peptide
(Lukanova et al, in press). This prospective study was based on
women who had not been using HRT during the 6 months (or
more) preceding blood donation.
Our stratification of analyses by HRT users and nonusers was
motivated by the suspicion that current or recent use of HRT
might have altered levels of circulating insulin, IGF-I, or IGFBPs.
We observed more elevated levels of IGF-I among HRT users, as
well as among users of OCs, in both the case and the control
groups. This observation might seem at variance with findings
from previous studies, where (current) use of exogenous oestro-
gens for OCs or HRT was generally associated with a decrease in
circulating IGF-I levels. A difference between those studies and
ours, however, is that ours included only ex-users of exogenous
hormones (though including recent use), whereas the previous
studies were generally on women still using OCs or HRT at the
time of blood donation. Among controls only, our study showed
lower levels of insulin and IGFBP-3 and higher levels of IGFBP-1,
among the nonusers of HRT.
Unexpectedly, the risk showed an inverse association with levels
of insulin and a strong direct association with levels of IGFBP-1,
among women who were or had been regularly using HRT. We
have no clear explanation for these inverse findings, compared to
our study hypotheses. Our study was carefully designed as a
population-based case–control study with detailed questionnaire
information on pre-existing illnesses and use of medications, and
the contrasting findings could not be explained by confounding by
history of diabetes mellitus, physical activity levels, menopausal
status, or type of exogenous hormones preparations used.
General concerns in case–control studies on endogenous
hormones and cancer risk are possible selection bias, or bias that
may be caused by differences between the case and control groups
in methods for blood collection, processing, and storage. Selection
bias could have occurred if nonparticipation in the study was
related differently to insulin, IGF-I, or IGFBP-1 levels among
eligible cases and controls. Among cases, the principal reason for
nonparticipation was the failure of the hospital staff to collect
blood samples, a reflection of the characteristics of the medical
personnel and not of the patients.
Another theoretical source of bias would be influences of a
tumour on circulating levels of IGF-I, IGFBPs, or insulin. IGF-I and
IGFBPs are produced not only in the liver – by far the major
source of these peptides in the circulation – but also by most other
tissues, including the endometrium. Circulating levels of IGF-I and
IGFBP-3 are relatively high, however (about 500–1000 times the
concentration of insulin, for example), and it is very unlikely that
increased synthesis of IGF-I or IGFBP-3 by tumours would
substantially alter circulating levels. Nevertheless, one specific
IGF-binding protein known to be produced in excess by some
tumour types (e.g. colorectum, prostate) is IGFBP-2, and this may
lead to some increase in circulating levels (which are much lower
than those of IGF-I and IGFBP-3). However, this binding protein
was not measured in the present study.
With respect to the laboratory assays, analysts were blinded to
the case or control status of the samples, and hence could not have
led to any systematic observation bias. However, one possible
source of bias that could explain case–control differences in the
levels of insulin as well as IGFBP-1 would be the differences in
fasting vs nonfasting conditions of cases and controls at the time of
blood sampling as (IGFBP-1 levels drop acutely as insulin rises,
after food consumption). Another possibility would have been an
increase in IGFBP-1 levels due to elevated cortisol, which stimulates
hepatic IGFBP-1 synthesis, and which might reflect greater
psychological stress among the cancer patients, for example. While
such factors might have explained a global case–control difference
in the levels of these hormones, it is less evident how they would
have led to case–control differences in the relationship of risk with
hormone levels within subgroups of HRT users and nonusers
separately. However, we cannot exclude the play of chance in our
findings, particularly in small subgroups such as HRT users.
Globally, risk was not associated with levels of circulating levels
of IGF-I. Over 80% of IGF-I in the circulation originates from the
liver. The main physiological stimulus for hepatic IGF-I synthesis
is growth hormone. In endometrial tissue, however, oestrogens
provide the main stimulus for IGF-I synthesis. Given these
differences in physiology, it is quite possible that, contrary to
several other forms of cancer (Kaaks and Lukanova, 2001),
endometrial cancer risk is relatively independent of circulating
IGF-I levels. In some other, small case–control studies, cases were
found to have lower levels of IGF-I. Among HRT users, we
observed an increased risk of endometrial cancer among women in
the lowest quartile level of IGF-I (P for trend¼0.23), which
remained after adjustment for BMI.
In conclusion, our study does not show any evidence of
an overall association between endometrial cancer risk and
serum levels of IGF-1, IGFBP-1, IGFBP-3, and insulin. Our
suggestive finding of an association between IGFBP-1 levels and
endometrial cancer risk among women who used HRT needs
confirmation by a study with greater statistical power to detect
weak associations.
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